Back to mobile site

iRhythm studies show extended monitoring detects more arrhythmias

April 27, 2026 8:05 AM EDT

iRhythm Holdings Inc. (NASDAQ: IRTC) presented data at the Heart Rhythm Society's annual meeting showing that short-term cardiac monitoring misses significant arrhythmias in post-ablation and pregnancy patients.

The company analyzed 11,051 patients who underwent atrial fibrillation ablation and used Zio ambulatory ECG devices for monitoring. The study found that 26% of patients had their first detected AF recurrence beyond 48 hours, suggesting that standard 24-48 hour Holter monitoring would miss these cases. Among patients with paroxysmal AF, 29.8% had recurrence detected after 48 hours.

A separate study examined 486 pregnant women using extended monitoring. Arrhythmias were detected in 37.7% of patients, with clinically significant arrhythmias found in 13.6%. Notably, 60% of arrhythmias were first detected after 48 hours of monitoring.

"Monitoring of 48 hours or less leads to false negatives of AF recurrence in 30% of those monitored in the year following-PVI," said Mintu Turakhia, Chief Medical and Scientific Officer at iRhythm.

The findings have implications for clinical decision-making, particularly regarding anticoagulation management after ablation procedures. The OCEAN trial, which used 24-48 hour monitoring strategies, may have missed AF recurrence in a substantial portion of patients based on these results.

For the pregnancy study, the median analyzable time was 99.2%, indicating high-quality data collection during extended monitoring periods. The research addresses a gap in evidence for arrhythmia detection during pregnancy, where cardiovascular disease remains a leading cause of pregnancy-related deaths.

The studies add to iRhythm's clinical evidence supporting extended cardiac monitoring over shorter-duration alternatives for comprehensive arrhythmia detection across patient populations.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

S1, Maynard Um, Mark Zuckerberg, ARK